Abstract
In a variant proportion of patients presenting with chest pain and electrocardiographic changes characteristic for ST – elevation myocardial infarction, percutaneous coronary intervention achieves epicardial coronary artery reperfusion but not the myocardial reperfusion (ranging from 5% to 50%). Furthermore, prolonged myocardial ischemia often breaks down the coronary microvasculature and the flow to the infarct myocardium may seem to be markedly reduced. This condition is known as no reflow – phenomenon. The no reflow - phenomenon is associated with an increased incidence of malignant ventricular arrhythmias, heart failure and 30-days mortality. In the recent years in literature, several articles (subsequently discussed in the present review) have been published and made relevant to the study of the pathophysiology regarding no reflow – phenomenon. This knowledge has assisted in the development of new treatment strategies, such as prophylactic use of vasodilators, mechanical devices and drugs inhibiting platelet.
The review has focused on the current literature about intra – coronary injection of drugs to treat no – reflow and microvascular dysfunction.
Keywords: No – reflow phenomenon, microcirculatory dysfunction, acute myocardial infarction, primary coronary intervention, percutaneous coronary intervention, microcirculatory dysfunction, intracoronary drug, vascular resistance, thrombus, distal embolization.
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:Intracoronary Injection of Drugs to Treat No – Reflow Phenomenon and Microcirculatory Dysfunction
Volume: 11 Issue: 2
Author(s): Andrea Rognoni, Alessandro Lupi, Chiara Cavallino, Gioel Gabrio Secco, Roberta Rosso and Angelo Sante Bongo
Affiliation:
Keywords: No – reflow phenomenon, microcirculatory dysfunction, acute myocardial infarction, primary coronary intervention, percutaneous coronary intervention, microcirculatory dysfunction, intracoronary drug, vascular resistance, thrombus, distal embolization.
Abstract: In a variant proportion of patients presenting with chest pain and electrocardiographic changes characteristic for ST – elevation myocardial infarction, percutaneous coronary intervention achieves epicardial coronary artery reperfusion but not the myocardial reperfusion (ranging from 5% to 50%). Furthermore, prolonged myocardial ischemia often breaks down the coronary microvasculature and the flow to the infarct myocardium may seem to be markedly reduced. This condition is known as no reflow – phenomenon. The no reflow - phenomenon is associated with an increased incidence of malignant ventricular arrhythmias, heart failure and 30-days mortality. In the recent years in literature, several articles (subsequently discussed in the present review) have been published and made relevant to the study of the pathophysiology regarding no reflow – phenomenon. This knowledge has assisted in the development of new treatment strategies, such as prophylactic use of vasodilators, mechanical devices and drugs inhibiting platelet.
The review has focused on the current literature about intra – coronary injection of drugs to treat no – reflow and microvascular dysfunction.
Export Options
About this article
Cite this article as:
Rognoni Andrea, Lupi Alessandro, Cavallino Chiara, Secco Gioel Gabrio, Rosso Roberta and Bongo Angelo Sante, Intracoronary Injection of Drugs to Treat No – Reflow Phenomenon and Microcirculatory Dysfunction, Cardiovascular & Hematological Agents in Medicinal Chemistry 2013; 11 (2) . https://dx.doi.org/10.2174/1871525711311020002
DOI https://dx.doi.org/10.2174/1871525711311020002 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Bone Marrow Stem Cell Therapy for Myocardial Angiogenesis
Current Vascular Pharmacology Editors Perspective (Throwing Caution to the Wnts)
Current Neurovascular Research Lipid Nanoparticles as Vehicles for Macromolecules: Nucleic Acids and Peptides
Recent Patents on Drug Delivery & Formulation Patent Selections
Recent Patents on Cardiovascular Drug Discovery Effect of Aging On Angiogenesis and Arteriogenesis
Current Cardiology Reviews Generation of Mesenchymal Stem Cells by Blood Cell Reprogramming
Current Stem Cell Research & Therapy The Role of Dietary Compounds in the Therapy of Nicotine-Induced Osteoporosis
Current Drug Targets Beta-Blockers in the Treatment of Dilated Cardiomyopathy: Which is the Best?
Current Pharmaceutical Design Free Radicals in Living Systems: In Vivo Detection of Bioradicals with EPR Spectroscopy
Current Organic Chemistry The Pharmacology of Diabetic Complications
Current Medicinal Chemistry The Toll-Like Receptor Radical Cycle Pathway: A New Drug Target in Immune-Related Chronic Fatigue
CNS & Neurological Disorders - Drug Targets Colloidal and Pharmacological Activity of Albumin in Clinical Fluid Management:Recent Developments
Current Drug Therapy The Synthesis of Coenzyme Q10
Current Organic Chemistry Inducible Nitric Oxide Synthase as a Possible Target in Hypertension
Current Drug Targets Coagulation Factor XIIIA (F13A1): Novel Perspectives in Treatment and Pharmacogenetics
Current Pharmaceutical Design Immunossupressant and Organ Transplantation: Immunophilins Targeting Agent and Alternative Therapies
Current Medicinal Chemistry New Frontiers in Regenerative Medicine in Cardiology: The Potential of Wharton’s Jelly Mesenchymal Stem Cells
Current Stem Cell Research & Therapy The Fetal Cardiac Function
Current Cardiology Reviews Natriuretic Peptides in Coronary Disease With Non-ST Elevation: New Tools Ready for Clinical Application?
Recent Patents on Cardiovascular Drug Discovery Single Photon Emission Tomography in the Diagnostic Assessment of Cardiac and Vascular Infectious Diseases
Current Radiopharmaceuticals